During the past decade, McGill Center for Studies in Aging conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 3 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "McGill Center for Studies in Aging" #1 sponsor was "Washington University School of Medicine" with 4 trials, followed by "TauRx Therapeutics Ltd" with 2 trials sponsored, "Biogen" with 1 trials sponsored, "Cephalon" with 1 trials sponsored and "McGill University" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "McGill Center for Studies in Aging" #1 collaborator was "National Institute on Aging (NIA)" with 5 trials as a collaborator, "Alzheimer's Association" with 4 trials as a collaborator, "Accelerating Medicines Partnership (AMP)" with 3 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator and "Hoffmann-La Roche" with 3 trials as a collaborator. Other collaborators include 19 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "McGill Center for Studies in Aging" are "Dementia" (5 trials), "Alzheimers Disease" (4 trials), "Alzheimers Disease, Familial" (4 trials), "Alzheimer Disease" (2 trials) and "Alzheimer's Disease" (2 trials). Many other conditions were trialed in "McGill Center for Studies in Aging" in a lesser frequency.

Most popular intervention types in "McGill Center for Studies in Aging" are "Drug" (10 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Gantenerumab" (3 trials), "Matching Placebo (Gantenerumab)" (3 trials), "E2814" (2 trials), "Lecanemab" (2 trials) and "Matching Placebo (E2814)" (2 trials). Other intervention names were less common.

The vast majority of trials in "McGill Center for Studies in Aging" are 11 trials for "All" genders.

Currently, there are NaN active trials in "McGill Center for Studies in Aging". undefined are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in McGill Center for Studies in Aging, 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in McGill Center for Studies in Aging, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".